Image:
https://www.getnews.info/wp-content/uploads/2024/06/1718734196.jpeg
Skita offers reliable and efficient freight forwarding to the Chinese pharmaceutical and chemical industries. It provides a wide range of transportation options and can handle complex transportation challenges.
Qingdao, China – June 19, 2024 – A leading freight forwarding company in China, Skita is proud to offer highly reliable, efficient Freight Forwarding [https://www.air-skita.com/]services to the pharmaceutical and chemical industries. It is the most trusted freight-forwarder in these industries, offering a wide range of services, including air transportation, independent Customs Declaration and Inspection, and sea transport.
The company excels in cold chain transportation [https://www.air-skita.com/], dangerous goods transportation and many more. Skita has extensive experience in the import and export of liquid, powder and capsule cargoes.
One of its main strengths is the extensive network of warehouses in strategic locations throughout China. All goods are handled with care by the company, whether they are Chemicals, Capsules Granules Liquids Tablets Powders or Powders. It helps corporate individuals in Big Health Field to identify and respond to complex challenges, as well as to identify growth opportunities for their businesses.
Other than value-added services, the Chinese Freight Forwarder [https://www.air-skita.com/] offers a competitive edge through its EXW (Ex Works), DDP (Delivered Duty Paid), DDU (Delivered Duty Unpaid), and double clearing services. These services streamline the import and exported process for clients and save them time, effort and costs associated with customs clearance and duties.
Skita is committed to maintaining the highest standards in compliance and quality. The company conducts a number of appraisals each year, including Signal Digest and DGM appraisals, MSDS, and Shanghai Institute of Chemical Industry. These appraisals can save clients money on export and import expenses, while ensuring regulatory compliance.
In the first few months in 2024, the company has successfully conducted 5,800 appraisals. To continue to provide value to its clients, it offers discounts of between 50-20% for new appraisals performed by the end 2024. This initial discount is an additional incentive for businesses to partner up with Skita in order to meet their freight forwarding requirements.
Skita is a specialist in Plant Extracts, Pharmaceutical Intermediates and other industries. The company has developed long-term strategic transportation cooperation with trading companies, pharmaceutical factories and other global renown companies. This has solidified its position as an industry trusted partner.
Skita is proud to be a direct contact for transportation services. This eliminates middlemen and ensures competitive pricing for its clients. The company prioritizes efficiency, safety and cost-effectiveness for clients’ goods, while offering traceable cargo information throughout the entire process. It can help with CPHI and API ingredients and goods.
Skita is a name that has gained trust in the Chinese freight forwarding industry because of its unwavering commitment towards excellence and customer satisfaction.
The company continues its solidification as a preferred partner of businesses seeking secure and efficient transport services.
Skita
Skita, a leading freight-forwarding company in China, is known for its first-class Chinese freight-forwarding services. These include Chinese Airfreight Forwarder (CAF) and Chinese Seafreight Forwarder (CSF). It is a trusted and reliable partner in the industry.
For further information, visit https://www.air-skita.com/
Media Contact
Company Name: SKITA GLOBAL INT’L TRANSPRTATION Co. LTD
Email: Send Email [http://www.universalpressrelease.com/?pr=skita-is-becoming-the-most-reliable-freight-forwarder-for-the-pharmaceutical-and-chemical-industry]
Phone: 0086-532-58005657
Address:No. Address:55 Baishahe Road Liuting Airport
City: Qingdao
State: Shandong
Country: China
Website: https://www.air-skita.com/
This release has been published on openPR.